Prostate cancer is fundamentally driven by androgen signaling. Consequently, the clinical gold standard for advanced disease is Androgen Deprivation Therapy (ADT), which starves the tumor of the hormones it needs to grow. However, this treatment often acts as an evolutionary pressure rather than a cure. Over time, tumors adapt to low-androgen environments, transitioning into a lethal stage known as Castration-Resistant Prostate Cancer (CRPC).
Understanding why this transition occurs requires looking beyond a simple failure of therapy. Instead, research reveals a complex landscape of molecular "escape hatches"—adaptive mechanisms that allow the tumor to maintain growth signaling even when its primary fuel source is depleted.
The Persistence of Androgen Receptor Signaling
The most direct way a tumor survives ADT is by ensuring the Androgen Receptor (AR) remains active despite low systemic testosterone. This is not a single failure point but a multi-faceted survival strategy.
One primary mechanism is the dynamic upregulation of the receptor itself. Mu et al. identified a specific population of "intermediate" prostate cancer stem cells that drive tumor initiation and development. These cells respond to androgen deprivation by aggressively upregulating the AR, allowing the tumor to scavenge trace amounts of hormones and maintain signaling.
Furthermore, the regulation of AR transcription itself becomes a site of adaptation. Jia et al. demonstrated that the orphan nuclear receptor TLX contributes to androgen insensitivity by repressing AR transcription, suggesting that the tumor may modulate its own receptor levels to optimize survival in fluctuating environments. Beyond the receptor itself, Zhang et al. highlight how alterations in androgen metabolism allow the tumor to synthesize its own androgens or process precursors more efficiently, effectively bypassing the systemic blockade intended by ADT.
Metabolic and Epigenetic Rewiring
As tumors become resistant, they often undergo a "metabolic switch," changing how they generate energy and regulate their genetic software.
A key example of this is the role of circular RNAs in metabolic control. Zhong et al. discovered that an $m^6A$-modified circular RNA, circRBM33, acts as a master switch by stabilizing PDHA1 mRNA. This stabilization boosts mitochondrial respiration, providing the energy necessary for the tumor to progress even under the stress of hormone therapy.
Epigenetic regulators also play a dual role in metabolism and resistance. Yum et al. identified a feedback loop involving the epigenetic regulator EZH2 and the ketogenic enzyme HMGCS2. In resistant models, EZH2 represses ketone production; however, the authors found that supplementing with the ketone body $\beta$-hydroxybutyrate (BHB) can trigger the degradation of EZH2, potentially sensitizing the tumor to standard treatments. Similarly, Pecci et al. showed that BET proteins like BRD4 epigenetically regulate cell adhesion molecules through the long non-coding RNA H19, driving metastasis independently of the androgen receptor's status.
Bypass Signaling and Non-Androgen Pathways
When the AR pathway is successfully blocked, the tumor often activates "bypass" pathways—alternative signaling routes that promote cell cycle progression and survival.
- PI3K/AKT Pathway: Wang et al. found that the downregulation of miR-4638-5p in CRPC leads to the upregulation of Kidins220, which in turn activates the PI3K/AKT pathway, a major driver of cell survival and angiogenesis.
- Chemokine Signaling: The overexpression of the receptor CXCR7 has been identified by Luo et al. as a novel indicator and driver of resistance to second-generation antiandrogens like enzalutamide.
- Protein Methylation: Yan et al. demonstrated that the methylation of the FUBP1 protein by PRMT5 accelerates progression, offering a target that exists entirely outside traditional hormone signaling.
Towards Novel Therapeutic Strategies
The diversity of these resistance mechanisms explains why second-generation antiandrogens, while effective, often eventually fail (Dibitetto et al.). This has led to a search for broader interventions.
Computational approaches are now being used to identify new targets. Wang et al. utilized machine learning to identify CCNA2 and CKS2 as critical drivers of CRPC progression, leading to the potential repurposing of drugs like Aprepitant to inhibit growth. Other researchers are looking to natural compounds; Huang et al. showed that Fangchinoline can induce cell cycle arrest in hormone-refractory cells by modulating p27 and Cyclin D expression.
Ultimately, the transition to castration resistance is a shift from a hormone-dependent state to a multi-pathway, metabolically flexible state. By identifying specific biomarkers—such as the SLC28A3 genetic variant identified by Jo et al.—clinicians may eventually be able to predict which escape mechanisms a tumor is likely to use, allowing for more personalized and preemptive treatment strategies (Leung et al.).
Key Foundational Work
Network analysis of an in vitro model of androgen-resistance in prostate cancer (2015) — contributed 1 concept elements to this direction.
Fangchinoline Induced G1/S Arrest by Modulating Expression of p27, PCNA, and Cyclin D in Human Prostate Carcinoma Cancer PC3 Cells and Tumor Xenograft (2010) — contributed 1 concept elements to this direction.